Core Viewpoint - Ardent Health's Q3 2025 financial results significantly disappointed investors, leading to a 33% drop in share price after missing consensus EPS estimates and revealing adverse non-recurring items [1][4]. Financial Performance - The company reported an EPS of -$0.17, a decrease of 189% compared to the same period last year, which was well below market expectations [4]. - A $43 million adjustment was made that reduced revenue for the quarter due to a change in the estimation technique for accounts receivable collectability [4]. - Ardent Health increased its professional and general liability reserves by $54 million, attributed to adverse developments in prior period claims related to settlements and ongoing litigation [5]. - The adjusted EBITDA guidance for 2025 was significantly lowered to $530-$550 million from a previous range of $575-$615 million, marking a 9% decrease at the midpoint [5]. Market Reaction - Following the disappointing financial results, Ardent Health's share price fell sharply, reflecting investor concerns over the company's financial health and operational issues [5]. Legal Investigation - Hagens Berman, a shareholder rights law firm, has initiated an investigation into potential violations of federal securities laws by Ardent Health, focusing on the accuracy of the company's financial statements and internal controls [2][3]. - The investigation aims to determine if company leadership was aware of issues related to revenue accounting and whether the reserve increase was timely [6].